Edition:
India

Five Prime Therapeutics Inc (FPRX.OQ)

FPRX.OQ on NASDAQ Stock Exchange Global Select Market

5.78USD
20 Aug 2019
Change (% chg)

$0.00 (+0.00%)
Prev Close
$5.78
Open
$5.88
Day's High
$5.91
Day's Low
$5.68
Volume
46,759
Avg. Vol
137,029
52-wk High
$15.06
52-wk Low
$4.89

Latest Key Developments (Source: Significant Developments)

Five Prime Therapeutics Q1 Loss Per Share $1.02
Thursday, 9 May 2019 

May 8 (Reuters) - Five Prime Therapeutics Inc ::FIVE PRIME THERAPEUTICS REPORTS FIRST QUARTER 2019 RESULTS.Q1 LOSS PER SHARE $1.02.Q1 EARNINGS PER SHARE ESTIMATE $-1.06 -- REFINITIV IBES DATA.CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES TOTALED $237.0 MILLION AS OF MARCH 31, 2019.FIVE PRIME EXPECTS FULL-YEAR 2019 NET CASH USED IN OPERATING ACTIVITIES TO BE BETWEEN $117 AND $122 MILLION.ESTIMATES ENDING 2019 WITH CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES BETWEEN $148 AND $153 MILLION.  Full Article

Five Prime Therapeutics Inc Files For Stock Shelf Of Up To $250 Million
Wednesday, 7 Nov 2018 

Nov 6 (Reuters) - Five Prime Therapeutics Inc ::FIVE PRIME THERAPEUTICS INC FILES FOR STOCK SHELF OF UP TO $250 MILLION .  Full Article

Five Prime Therapeutics Announces Third Quarter 2018 Financial Results
Wednesday, 7 Nov 2018 

Nov 6 (Reuters) - Five Prime Therapeutics Inc ::FIVE PRIME THERAPEUTICS ANNOUNCES THIRD QUARTER 2018 FINANCIAL RESULTS.Q3 LOSS PER SHARE $1.37.Q3 EARNINGS PER SHARE VIEW $-1.15 -- THOMSON REUTERS I/B/E/S.COLLABORATION AND LICENSE REVENUE FOR Q3 OF 2018 DECREASED BY $2.5 MILLION, OR 30%, TO $5.8 MILLION FROM $8.3 MILLION FOR Q3 OF 2017.FIVE PRIME EXPECTS FULL-YEAR 2018 NET CASH USED IN OPERATING ACTIVITIES TO BE LESS THAN $135 MILLION.NOW ESTIMATES ENDING 2018 WITH APPROXIMATELY $265 MILLION IN CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES.  Full Article

Five Prime Therapeutics Names David Smith CFO
Monday, 5 Nov 2018 

Nov 5 (Reuters) - Five Prime Therapeutics Inc ::FIVE PRIME THERAPEUTICS SAYS DAVID SMITH WILL JOIN CO AS CFO, EFFECTIVE AS OF NOVEMBER 26, 2018 - SEC FILING.FIVE PRIME THERAPEUTICS - EFFECTIVE AS OF NOV 26, 2018, LINDA RUBINSTEIN WILL CEASE TO SERVE AS FIVEPRIME'S INTERIM CFO.  Full Article

Personal Genome Diagnostics enteres into a collaboration with Five Prime Therapeutics
Tuesday, 3 Apr 2018 

April 3 (Reuters) - Five Prime Therapeutics Inc ::ONCOLOGY DRUG CANDIDATE BEMARITUZUMAB.CO INTENDS TO SUBMIT ASSAY FOR REGULATORY APPROVAL, COMMERCIALIZE IN U.S., EUROPE, JAPAN, CHINA, OTHER COUNTRIES.FINANCIAL TERMS OF AGREEMENT WERE NOT DISCLOSED.  Full Article

Five Prime Therapeutics Announces Executive Change
Wednesday, 14 Mar 2018 

March 13 (Reuters) - Five Prime Therapeutics Inc ::FIVE PRIME THERAPEUTICS ANNOUNCES EXECUTIVE CHANGE.SAYS CFO MARC BELSKY RESIGNED.‍BELSKY WILL CONTINUE IN HIS CURRENT ROLE UNTIL APRIL 6, 2018​.  Full Article

Five Prime Reports Q4 Loss Per Share $1.04
Wednesday, 28 Feb 2018 

Feb 27 (Reuters) - Five Prime Therapeutics Inc ::FIVE PRIME ANNOUNCES FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS.Q4 LOSS PER SHARE $1.04.FIVE PRIME THERAPEUTICS - CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES TOTALED $292.7 MILLION ON DEC 31, 2017 VERSUS $421.7 MILLION ON DECEMBER 31, 2016.  Full Article

Five Prime Therapeutics Earns IND Milestone Payment Under Immune Checkpoint Pathways Discovery Collaboration With Bristol-Myers Squibb
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Five Prime Therapeutics Inc ::FIVE PRIME THERAPEUTICS EARNS IND MILESTONE PAYMENT UNDER IMMUNE CHECKPOINT PATHWAYS DISCOVERY COLLABORATION WITH BRISTOL-MYERS SQUIBB AND ANNOUNCES THAT BMS HAS EXTENDED THE RESEARCH TERM OF THIS COLLABORATION FOR A SECOND TIME.FIVE PRIME THERAPEUTICS INC - MILESTONE FOR ANTIBODY TARGETING TIM-3 TRIGGERS $5 MILLION PAYMENT TO FIVE PRIME.FIVE PRIME- BMS EXTENDS RESEARCH COLLABORATION TERM FOR DEVELOPMENT, COMMERCIALIZATION FOR THERAPEUTICS IN 3 IMMUNE CHECKPOINT PATHWAYS TO MARCH 2019.FIVE PRIME THERAPEUTICS INC - BRISTOL-MYERS SQUIBB WILL ALSO PROVIDE ADDITIONAL FUNDING TO FIVE PRIME FOR EXTENDED TERM OF RESEARCH COLLABORATION.  Full Article

Five Prime Therapeutics Submits Investigational New Drug Application For FPA150
Thursday, 4 Jan 2018 

Jan 3 (Reuters) - Five Prime Therapeutics Inc ::FIVE PRIME THERAPEUTICS SUBMITS INVESTIGATIONAL NEW DRUG APPLICATION FOR NOVEL B7-H4 ANTIBODY FPA150.FIVE PRIME THERAPEUTICS INC - ANTICIPATES INITIATING A PHASE 1 TRIAL OF FPA150 DURING FIRST HALF OF 2018.  Full Article

Five Prime Therapeutics And Zai Lab Announce Exclusive License Agreement
Wednesday, 20 Dec 2017 

Dec 19 (Reuters) - Five Prime Therapeutics Inc ::FIVE PRIME THERAPEUTICS AND ZAI LAB ANNOUNCE EXCLUSIVE LICENSE AGREEMENT FOR FPA144 ANTI-FGFR2B ANTIBODY IN GREATER CHINA AND GLOBAL STRATEGIC DEVELOPMENT COLLABORATION.FIVE PRIME THERAPEUTICS - GRANTED ZAI LAB AN EXCLUSIVE LICENSE TO DEVELOP AND COMMERCIALIZE FPA144 IN GREATER CHINA TERRITORY​.FIVE PRIME THERAPEUTICS INC - ‍ZAI LAB WILL BE RESPONSIBLE FOR CONDUCTING PHASE 3 FIGHT TRIAL IN GREATER CHINA​.  Full Article